COVİD-19 AŞISI SONRASI GELİŞEN PERİKARDİYAL EFÜZYON VE KARDİYAK TAMPONAD: NADİR BİR OLGU SUNUMU

Year 2022, Volume: 29 Issue: 2, 261 - 263, 30.06.2022

Muammer Karakayalı Yusuf Oflu

https://doi.org/10.17343/sdutfd.999473

Cited By: 1

Abstract

Bilinen kronik hastalık öyküsü olmayan 44 yaşında
kadın hasta, covid-19 aşısı (Pfizer-Biontech) sonrası
taşikardi ve nefes darlığı şikayetiyle acil servise başvurdu.
Kardiyolojiye konsülte edilen hastanın tansiyonu:
80/40 mmHg. Ekokardiyografi (EKO): Ejeksiyon
Fraksiyonu %65, en geniş noktasında kalbi çepeçevre
saran ve sağ kalp boşluklarını diyastolde kollabe
ederek tamponad kliniğini oluşturan 5 cm perikardiyal
efüzyon (PE) mevcuttu. Hastaya acil perikardiyosentez
uygulandı. Hastanın perikardiyal sıvı içeriği seröz
idi. Perikardiyosentez sonrası klinik durumu stabilize
olan hasta koroner yoğun bakım ünitesinde takip
edildi. Takiplerinde kontrol ekoda perikardiyal efüzyon
izlenmedi. Hastanın Covid-19 a yönelik yapılan PCR
sonuçları negatifti. Hasta kardiyoloji poliklinik kontrolü
ile taburcu edildi.

Keywords

Covid-19, Perikardiyal efüzyon, Aşı, Kardiyak tamponad.

PERICARDIAL EFFUSION AND CARDIAC TAMPONADE AFTER COVID-19 VACCINE: A RARE CASE REPORT

Abstract

A 44-year-old female patient with no known history
of chronic disease was admitted to the emergency
room with tachycardia and shortness of breath after
covid-19 vaccine (Pfizer Biontech). The blood pressure
of the patient who was consulted to cardiology: 80/40
mmHg. Echocardiography (ECHO): Ejection Fraction
was 65%, pericardial effusion (PE) was present at
its widest point, 5 cm encircling the heart, collapsing
the right heart cavities in diastole, forming the clinic
of tamponade. Emergency pericardiocentesis was
applied to the patient. Pericardial fluid content of the
patient was serous. The patient, whose clinical stability
was stabilized after pericardiocentesis, was followed in
the coronary intensive care unit. No pericardial effusion
was observed in the control echo duringfollow-up.
Thepatient's PCR results were negative. The patient
was discharged with cardiology outpatient control.

Keywords

Covid-19, Pericardial effusion, Vaccine, Cardiac tamponade.

References

• World Health Organization. Geneva (Switzerland): Novel coronavirus (2019-nCoV), situation report-1, 21 January 2020 [Internet] [cited 2020 Mar 2]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf
• Farina A, Uccello G, Spreafico M et al. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. Eur J InternMed 2020;76:100–01.
• Dabbagh MF, Aurora L, D’Souza P et al. Cardiac tamponade secondary to COVID-19. JACC Case Rep 2020;2:1326–30.
• Purohit R, Kanwal A, Pandit A. Acute myopericarditis with pericardial effusion and cardiac tamponade in a patient with COVID-19. Am J Case Rep 2020;21:e925554.
• Asif T, Kassab K, Iskander F et al. Acute pericarditis and cardiac tamponade in a patient with COVID-19: a therapeutic challenge. Eur J Case RepInternMed 2020;7:001701.
• Hua A, O’Gallagher K, Sado D et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. EurHeart J 2020;41:2130.
• Fox K, Prokup JA, Butson K et. al: Acute effusive pericarditis: a late complication of COVID-19 . Cureus. 2020, 12:9074. 10.7759/cureus.9074.
• Dong N, Cai J, Zhou Y et al. End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV. JACC Heart Fail 2020;8:515–17.
• Jin Y, Yang H, Ji W et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12:372.
• Xu Z, Shi L, Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420.